Lisinopril Tablet
NDC Package 76282-421-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Lisinopril tablets is lisinopril is used to treat high blood pressure. This formulation utilizes a tablet delivery system. Marketed by Exelan Pharmaceuticals Inc., this product is identified by NDC 76282-421 and is authorized under FDA application ANDA203508.

Identification & Billing

NDC Package Code
76282-421-30
Package Description
30 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
76282042130
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Lisinopril
Non-Proprietary Name
Lisinopril
Substance Name
Lisinopril
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Lisinopril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat heart failure and to improve survival after a heart attack. Lisinopril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.

Regulatory & Marketing

Labeler Name
Exelan Pharmaceuticals Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA203508
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-22-2017
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (76282-421). Click a package code to view its specific billing and regulatory data.

100 TABLET in 1 BOTTLE
500 TABLET in 1 BOTTLE
1000 TABLET in 1 BOTTLE
180 TABLET in 1 BOTTLE
45 TABLET in 1 BOTTLE
90 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 76282-421-30 identifies a specific commercial package of 30 tablet in 1 bottle of Lisinopril, a human prescription drug labeled by Exelan Pharmaceuticals Inc.. This tablet is formulated for oral use and contains lisinopril as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Exelan Pharmaceuticals Inc. on March 22, 2017. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Lisinopril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat heart failure and to improve survival after a heart attack. Lisinopril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.

How is this Exelan Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 76282042130. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
76282-421-30
11-Digit CMS (5-4-2)
76282-0421-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.